Veracyte, Inc. Veracyte, Inc.

Veracyte, Inc.

VCYT

Rangering i aksjer #4361
Veracyte, Inc. operates as a diagnostics company in the United States and... Veracyte, Inc. operates as a diagnostics company in the United States and internationally. The company offers Afirma Genomic Sequencing Classifier for cancerous thyroid nodules; Decipher Prostate Genomic Classifiers for prostate cancer diagnosis; Decipher Bladder Genomic Classifier for bladder cancer diagnosis; Prosigna Breast Cancer Assay for breast cancer diagnosis; and Percepta Nasal Swab Test for lung cancer diagnosis. It also provides the nCounter analysis system services. The company was formerly known as Calderome, Inc. and changed its name to Veracyte, Inc. in March 2008. Veracyte, Inc. was incorporated in 2006 and is headquartered in South San Francisco, California.
Aksjekurs
$44.93
Sist synkronisert: 2026-10-20
Markedsverdi
$3.61B
Endring (1 dag)
2.57%
Endring (1 år)
24.45%
Land
US
Handel Veracyte, Inc. (VCYT)

Kategori

Healthcare
Inntekter for Veracyte, Inc. (VCYT)
Inntekter i Jun 2026 TTM: $108.94M
Ifølge Veracyte, Inc. sine nyeste økonomiske rapporter er selskapets nåværende resultat $108.94M. I 2023 hadde selskapet et resultat på $-76.61M, en nedgang sammenlignet med resultatet i 2022, som var $-36.43M. Resultatet som vises på denne siden er resultat før renter og skatt, eller EBIT.
Inntektshistorikk for Veracyte, Inc. fra 2011 til 2026
Inntekter ved slutten av hvert år
År Inntekter Endre
2026 (TTM) $108.94M 323.17%
2024 $25.74M -133.60%
2023 $-76.61M 110.32%
2022 $-36.43M -55.39%
2021 $-81.65M 133.89%
2020 $-34.91M 177.08%
2019 $-12.60M -45.22%
2018 $-23.00M -25.82%
2017 $-31.00M -1.13%
2016 $-31.36M -6.96%
2015 $-33.70M 14.74%
2014 $-29.37M 14.83%
2013 $-25.58M 37.17%
2012 $-18.65M 29.10%
2011 $-14.45M 0.00%
Inntekter for lignende selskaper eller konkurrenter
Selskap Inntekter Forskjell i inntekter Land
$7.61B 6,884.58%
US
$4.76B 4,271.21%
US
$-252.70M -331.96%
US
- -
CN
$1.66B 1,421.94%
US